Eldersburg, MD, United States of America

Dana V Ferraris

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Eisai Corporation of North America. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dana V Ferraris. Retrieved from https://idiyas.com/inventor/dana-v-ferraris

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile



Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dana V Ferraris: Innovator in Pharmaceutical Compounds

Introduction

Dana V Ferraris is a notable inventor based in Eidersburg, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit PARP. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Dana V Ferraris holds a patent for "Compounds and their use." This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP. His patent represents a crucial step in the development of new therapeutic options for various diseases.

Career Highlights

Ferraris is currently employed at Eisai Corporation of North America, where he continues to work on groundbreaking pharmaceutical research. His role at the company allows him to collaborate with other talented professionals in the field, further enhancing his contributions to medical innovation.

Collaborations

One of his notable coworkers is Jia-He Li, who is also involved in the research and development of pharmaceutical compounds. Their collaboration exemplifies the teamwork necessary for successful innovation in the pharmaceutical industry.

Conclusion

Dana V Ferraris is a dedicated inventor whose work in pharmaceutical compounds has the potential to impact the medical field significantly. His patent and ongoing research at Eisai Corporation of North America highlight his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…